Clean Science and Technology Limited delivered a resilient performance for Q4 FY26, marked by a 8% sequential revenue growth to INR 193 crores and strong EBITDA margins of 46%. The company saw record revenues in its HALS business segment and successfully achieved positive EBITDA for its subsidiary, Clean Fino-Chem Limited. Despite global macro uncertainties, the company continues to focus on backward integration, product mix optimization, and capacity debottlenecking to drive future value.
Quarterly Financial Highlights
For the quarter ended March 31, 2026, Clean Science and Technology reported a stand-alone revenue of INR 193 crores, representing an 8% increase on a sequential basis. The company maintained robust operational efficiency, delivering an EBITDA of INR 88 crores (46% margin) and a PAT of INR 77 crores (40% margin). This performance was largely driven by increased customer volume offtake.
Strategic Business Developments
The company achieved a significant milestone with its subsidiary, Clean Fino-Chem Limited, which reported its first quarter of positive EBITDA at INR 7 crores. The Hydroquinone/Catechol plant, established in December 2025, has moved past the breakeven stage and is now in its stabilization phase. Furthermore, the company has successfully replaced all imported Hydroquinone and Catechol requirements with in-house production for its TBHQ and Veratrole product lines, leading to improved raw material cost moderation.
HALS Business Expansion
The HALS segment emerged as a key growth driver, achieving its highest-ever revenue in Q4 FY26 with a volume exceeding 1,000 tonnes for the quarter. The company is actively debottlenecking existing lines and setting up a dedicated production facility for HALS 2020, a key intermediate for higher-grade NOR-HALS products. Management noted that export exposure has risen significantly, now accounting for 50% of sales in select products.
Future Outlook and Capex
The company maintains a disciplined capital allocation strategy, with total investments in its subsidiary reaching INR 750 crores after a INR 200 crore infusion this year. Looking ahead, the company expects to commercialize its Performance Chemical 2 unit by September 2026. The Board has declared a final dividend of INR 4 per equity share, reflecting a 400% payout on the face value of INR 1 per share, demonstrating continued commitment to shareholder value.
Source: BSE
